DocGo Management
Management criteria checks 2/4
DocGo's CEO is Lee Bienstock, appointed in Sep 2023, has a tenure of 2.67 years. total yearly compensation is $3.57M, comprised of 22% salary and 78% bonuses, including company stock and options. directly owns 0.68% of the company’s shares, worth $416.65K. The average tenure of the management team and the board of directors is 3.4 years and 2 years respectively.
Key information
Lee Bienstock
Chief executive officer
US$3.6m
Total compensation
| CEO salary percentage | 21.98% |
| CEO tenure | 2.7yrs |
| CEO ownership | 0.7% |
| Management average tenure | 3.4yrs |
| Board average tenure | 2yrs |
Recent management updates
Recent updates
Narrative Update • Apr 23
DCGO: Transport EBITDA Outlook Will Drive Future Upside Potential
Analysts recently trimmed their DocGo price targets, with cuts such as Stifel's move from $4.00 to $2.50, citing mixed Q4 results, modestly higher 2026 transport guidance, and updated expectations for growth, margins, and P/E assumptions. Analyst Commentary Bullish analysts acknowledge the recent price target cuts but still point to several areas they see as supportive for DocGo's valuation and long term execution story.
Narrative Update • Apr 07
DCGO: Transport EBITDA And 2026 Guidance Will Drive Future Upside Potential
Narrative Update Analysts have nudged their price expectations for DocGo lower, trimming aggregate targets by around $0.10 as they factor in mixed Q4 results, modestly higher 2026 transport guidance, and updated views on margins, growth, and future P/E multiples. Analyst Commentary Recent Street commentary on DocGo is mixed, with some analysts focusing on potential value in the transport segment and others reacting to lower price targets and Q4 variability.Narrative Update • Mar 24
DCGO: Transport EBITDA Outlook Will Support Future Upside Potential
Narrative Update The analyst price target for DocGo has been reduced from $4.00 to $2.50, as analysts factor in mixed Q4 results while crediting modestly higher 2026 transport guidance and the view that the transport unit alone could potentially support proceeds above the current share price. Analyst Commentary Recent research reflects a more cautious stance on DocGo, with the price target reduced to US$2.50 while still crediting specific strengths in the transport segment.
Narrative Update • Mar 10
DCGO: Future Returns Will Rely On Expanding Telehealth Weight Loss Services
Analysts have trimmed their price targets on DocGo to reflect slightly softer revenue growth assumptions, along with somewhat stronger profit margin and future P/E expectations, resulting in only a modest adjustment to their overall valuation view. What's in the News Nasdaq notified DocGo on January 26, 2026 that the company is not in compliance with the $1.00 minimum bid price requirement.Narrative Update • Feb 22
DCGO: Buyback Extension And Telehealth Expansion Will Support Future Upside
Analysts have trimmed their price targets on DocGo to $2.50, citing slightly higher discount rate assumptions, a modestly softer profit margin outlook, and a higher future P/E multiple as key drivers of the revised view. What's in the News Nasdaq notified DocGo on January 26, 2026 that the company is not in compliance with the minimum US$1.00 bid price requirement, triggering a 180 day window until July 27, 2026 to regain compliance before potential further action is considered (Delistings).Narrative Update • Feb 08
DCGO: Future Returns Will Rely On Expanding Longitudinal Virtual Weight Loss Care
Analysts have slightly reduced their price target on DocGo, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. This adjustment signals a more cautious stance on the company’s risk and earnings profile.Narrative Update • Jan 24
DCGO: Buyback Extension And M&A Pipeline Will Support Future Upside
Analysts have trimmed their price target on DocGo to reflect a fair value shift from about $3.08 to roughly $2.50. The change reflects updated assumptions around revenue contraction, slightly higher required returns, modestly better profit margins, and a lower future P/E multiple.Narrative Update • Jan 10
DCGO: Future Returns Will Depend On Expanding Longitudinal Care Partnerships
Analysts have made a small upward tweak to their price target on DocGo, reflecting slightly more constructive assumptions around revenue growth and long term profit margins, while keeping the projected P/E and discount rate almost unchanged. What's in the News Robbins Geller Rudman & Dowd LLP announced a proposed US$12.5 million cash settlement in the DocGo securities class action, subject to court approval at a hearing scheduled for March 24, 2026 in the Southern District of New York (Lawsuits & Legal Issues).Narrative Update • Dec 26
DCGO: Future Returns Will Depend On Longitudinal Care And Maturing Revenue Mix
Analysts have nudged up their price target on DocGo by a modest amount, citing slightly higher long term profit margin expectations and a marginally richer future earnings multiple. Together, these factors support a small increase in estimated fair value.Narrative Update • Dec 12
DCGO: Future Returns Will Depend On New Longitudinal Care Contracts
Analysts have lowered their price target on DocGo from approximately 1.60 dollars to 1.00 dollars, citing a higher required discount rate and a reduced valuation multiple, despite modest improvements in the projected revenue trajectory and profit margins. What's in the News DocGo signaled an active mergers and acquisitions strategy, highlighting its ability to acquire traditional health care assets and layer on its technology and mobile health capabilities to support long-term growth and shareholder value (company commentary) The company provided updated guidance, forecasting 2025 revenue of 315 million to 320 million dollars, including 68 million to 70 million dollars from migrant-related contracts, and 2026 revenue of 280 million to 300 million dollars with no migrant-related revenue (corporate guidance) DocGo recorded a goodwill impairment charge of approximately 8.7 million dollars in the third quarter of 2025, reflecting a write-down of acquired assets (company filing) DocGo announced a new Longitudinal Care Services program with a California-based insurer, targeting 10,000 under-engaged members with combined telehealth and in-home clinical services starting in the fourth quarter (client announcement) The company is expanding its partnership with a national insurer in New Mexico, launching care gap closure and planned primary care services for 10,000 Turquoise Care members through at-home visits and chronic care support (client announcement) Valuation Changes The fair value estimate has fallen significantly from approximately $1.60 to $1.00 per share.Analysis Article • Sep 26
Benign Growth For DocGo Inc. (NASDAQ:DCGO) Underpins Its Share Price
When close to half the companies operating in the Healthcare industry in the United States have price-to-sales ratios...Analysis Article • May 16
DocGo Inc. (NASDAQ:DCGO) Looks Inexpensive After Falling 38% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the DocGo Inc. ( NASDAQ:DCGO ) share price has dived 38% in the last thirty days...Analysis Article • Apr 16
Is It Too Late To Consider Buying DocGo Inc. (NASDAQ:DCGO)?
DocGo Inc. ( NASDAQ:DCGO ), might not be a large cap stock, but it saw significant share price movement during recent...Analysis Article • Mar 06
We Like The Quality Of DocGo's (NASDAQ:DCGO) Earnings
Despite posting healthy earnings, DocGo Inc.'s ( NASDAQ:DCGO ) stock has been quite weak. We have done some analysis...Analysis Article • Mar 01
These 4 Measures Indicate That DocGo (NASDAQ:DCGO) Is Using Debt Safely
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Feb 11
Subdued Growth No Barrier To DocGo Inc. (NASDAQ:DCGO) With Shares Advancing 33%
DocGo Inc. ( NASDAQ:DCGO ) shareholders have had their patience rewarded with a 33% share price jump in the last month...
New Narrative • Sep 24
Innovative Health Initiatives Promise Growth Amid Analysts' Concerns Over Future Earnings And Margins
Strategic partnerships with virtual-only providers and operational efficiency improvements indicate a comprehensive approach to expanding health solutions and improving margins.Analysis Article • Aug 05
DocGo Inc. (NASDAQ:DCGO) Doing What It Can To Lift Shares
DocGo Inc.'s ( NASDAQ:DCGO ) price-to-earnings (or "P/E") ratio of 15.3x might make it look like a buy right now...Analysis Article • Jul 17
At US$3.40, Is DocGo Inc. (NASDAQ:DCGO) Worth Looking At Closely?
DocGo Inc. ( NASDAQ:DCGO ), might not be a large cap stock, but it saw a decent share price growth of 20% on the...Analysis Article • Jun 11
These 4 Measures Indicate That DocGo (NASDAQ:DCGO) Is Using Debt Safely
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Seeking Alpha • Mar 20
DocGo: Upside Remains Attractive After Share Price Decline
Summary DocGo stock receives a buy rating due to attractive upside potential and commendable execution demonstrated by management. Recent results show strong revenue growth and margin expansion, driven by steady contracts and growth in trip volumes and average price. Management's positive commentary, impressive pipeline, and plans for RFP submissions in FY24 indicate continued momentum and cross-sell success. Read the full article on Seeking AlphaAnalysis Article • Feb 13
Does DocGo (NASDAQ:DCGO) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Feb 05
DocGo: Good Performance, Trust Issues
Summary DocGo has recently faced a series of negative events, including criticism from the NY Times, Comptroller contract rejection, CEO departure on false CV allegations, and a short report. Despite these challenges, the company presented strong Q3 2023 results, positively revised FY 2023 guidance, addressed the short report, announced new partnerships and a share repurchase program. Investors must decide if they should trust DocGo's performance and financials or let the dust settle first. Read the full article on Seeking AlphaAnalysis Article • Jan 25
Why DocGo Inc. (NASDAQ:DCGO) Could Be Worth Watching
DocGo Inc. ( NASDAQ:DCGO ), might not be a large cap stock, but it led the NASDAQCM gainers with a relatively large...Analysis Article • Jan 04
Fewer Investors Than Expected Jumping On DocGo Inc. (NASDAQ:DCGO)
There wouldn't be many who think DocGo Inc.'s ( NASDAQ:DCGO ) price-to-sales (or "P/S") ratio of 1x is worth a mention...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | US$4m | US$785k | -US$182m |
| Sep 30 2025 | n/a | n/a | -US$52m |
| Jun 30 2025 | n/a | n/a | -US$18m |
| Mar 31 2025 | n/a | n/a | -US$641k |
| Dec 31 2024 | US$8m | US$785k | US$20m |
| Sep 30 2024 | n/a | n/a | US$31m |
| Jun 30 2024 | n/a | n/a | US$30m |
| Mar 31 2024 | n/a | n/a | US$22m |
| Dec 31 2023 | US$11m | US$582k | US$7m |
| Sep 30 2023 | n/a | n/a | US$7m |
| Jun 30 2023 | n/a | n/a | US$6m |
| Mar 31 2023 | n/a | n/a | US$20m |
| Dec 31 2022 | US$4m | US$415k | US$35m |
Compensation vs Market: Lee's total compensation ($USD3.57M) is above average for companies of similar size in the US market ($USD621.92K).
Compensation vs Earnings: Lee's compensation has been consistent with company performance over the past year.
CEO
Lee Bienstock (40 yo)
2.7yrs
Tenure
US$3,571,951
Compensation
Mr. Lee Bienstock served as President at DocGo Inc. since December 31, 2022 until September 15, 2023. He served as Chief Operating Officer at DocGo Inc. since March 2022 until September 15, 2023 and serves...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.7yrs | US$3.57m | 0.68% $ 416.6k | |
| Treasurer & CFO | 3.4yrs | US$1.70m | 0.35% $ 213.2k | |
| General Counsel | 4.5yrs | US$1.32m | 0.094% $ 57.5k | |
| Chief Information Officer | 1.7yrs | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Chief Compliance Officer | 4.2yrs | US$1.84m | 0.15% $ 91.9k | |
| Vice President of Human Resources | no data | no data | no data | |
| CEO of Clinical Practice Group & Member of Medical Advisory Board | no data | no data | no data |
3.4yrs
Average Tenure
53.5yo
Average Age
Experienced Management: DCGO's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.1yrs | US$3.57m | 0.68% $ 416.6k | |
| General Counsel | 4.5yrs | US$1.32m | 0.094% $ 57.5k | |
| CEO of Clinical Practice Group & Member of Medical Advisory Board | 1.9yrs | no data | no data | |
| Independent Director | 4.5yrs | US$225.50k | 0.61% $ 377.3k | |
| Independent Director | 4.5yrs | US$193.00k | 0.45% $ 278.1k | |
| Member of Medical Advisory Board | 1.9yrs | no data | no data | |
| Independent Non-Executive Chairman | 1.6yrs | US$400.00k | 0.015% $ 9.3k | |
| Member of Medical Advisory Board | 1.9yrs | no data | no data | |
| Independent Director | 3.5yrs | US$208.00k | 0.017% $ 10.2k | |
| Independent Director | 4.5yrs | US$234.25k | 0.057% $ 34.9k | |
| Chairman of Medical Advisory Board | 1.9yrs | no data | no data | |
| Member of Medical Advisory Board | 1.9yrs | no data | no data |
2.0yrs
Average Tenure
66yo
Average Age
Experienced Board: DCGO's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/07 11:16 |
| End of Day Share Price | 2026/05/07 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DocGo Inc. is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sarah James | Barclays |
| David Larsen | BTIG |
| Richard Close | Canaccord Genuity |